Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Link
http://www.nature.com/articles/leu2013235.pdf
Reference10 articles.
1. Yeo W, Johnson PJ . Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209–220.
2. Zerbini A, Pilli M, Boni C, Fisicaro P, Penna A, Di Vincenzo P et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134: 1470–1481.
3. Watanabe T, Tanaka Y . Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatol Res 2013; 43: 113–121.
4. Pardanani A . Ruxolitinib for myelofibrosis therapy: current context, pros and cons. Leukemia 2012; 26: 1449–1451.
5. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;; e-pub ahead of print 26 April 2013; doi:10.1038/leu.2013.119.
Cited by 106 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A safety evaluation of ruxolitinib for the treatment of polycythemia vera;Expert Opinion on Drug Safety;2023-12-29
2. Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib;World Journal of Hepatology;2023-11-27
3. Tofacitinib treatment of rheumatoid arthritis increases senescent T cell frequency in patients and limits T cell function in vitro;European Journal of Immunology;2023-05-31
4. Hepatitis B virus reactivation associated with Janus kinase (JAK) inhibitors: a retrospective study of pharmacovigilance databases and review of the literature;Expert Opinion on Drug Safety;2023-02-21
5. Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms;Biomedicine & Pharmacotherapy;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3